Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity
Journal of Rehabilitation Medicine · 2026
DOI: 10.2340/jrm.v58.45826 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Rehabilitation Medicine, 2026. Verfasst von Masahiro Abo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, The Jikei University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Muscle Spasticity, Neuromuscular Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the safety and effectiveness of “step-up dose” onabotulinumtoxinA (401–600 units per treatment session) in patients with upper and lower limb spasticity.
Design
Multicentre, prospective, observational, single-arm investigation. Subjects: A convenience sample of 109 patients with upper and lower limb spasticity scheduled to receive their first or second step-up dose onabotulinumtoxinA.
Methods
The study primarily evaluated the safety of step-up dose onabotulinumtoxinA by summarizing adverse events. Effectiveness was evaluated as a secondary objective.
Results
Of the safety population comprising 107 patients, 49 (45.8%) experienced at least 1 adverse event, with coronavirus disease 2019 and nasopharyngitis being the most frequent. Five patients (4.7%) reported adverse events related to onabotulinumtoxinA or injection procedure. These safety findings were generally consistent with those previously reported, while reduction of muscle tone and subsequent clinical benefits were suggested by the Modified Ashworth Scale and patient/physician-reported outcomes.
Conclusion
To the best of our knowledge, this is the first study to prospectively evaluate the safety and effectiveness of onabotulinumtoxinA at doses above 400 units given simultaneously for upper and lower limb spasticity. No new safety concern was identified for this “step-up dose” treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, The Jikei University Hospital, Tokyo, Japan.
- Department of Rehabilitation Medicine, Keiju Medical Center, Nanao, Japan.
- Department of Rehabilitation Medicine, Chiba Rehabilitation Center, Chiba, Japan.
- Department of Rehabilitation Medicine, St. Marianna University Hospital, Kawasaki, Japan.
- Department of Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, Japan.
- 6GlaxoSmithKline K.K., Tokyo, Japan. naho.x.oyanagi@gsk.com.
ORCID-Profile: Masahiro Abo, Naohisa Kikuchi, Nobuyuki Sasaki, Naho Ohyanagi, Yumi Yamazaki, Takao Mogi, Ai Hayashi
Zitieren
APA
Abo, M., Kawakita, S., Kikuchi, N., Sasaki, N., Shigematsu, T., Ohyanagi, N., Yamazaki, Y., Mogi, T., Yamashita, Y., & Hayashi, A. (2026). Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity. Journal of Rehabilitation Medicine. https://doi.org/10.2340/jrm.v58.45826
Vancouver
Abo M, Kawakita S, Kikuchi N, Sasaki N, Shigematsu T, Ohyanagi N, et al. Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity. Journal of Rehabilitation Medicine. 2026. doi:10.2340/jrm.v58.45826
BibTeX
@article{Abo2026,
author = {Abo, Masahiro and Kawakita, Shinichiro and Kikuchi, Naohisa and Sasaki, Nobuyuki and Shigematsu, Takashi and Ohyanagi, Naho and Yamazaki, Yumi and Mogi, Takao and Yamashita, Yoshiyuki and Hayashi, Ai},
title = {Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity},
journal = {Journal of Rehabilitation Medicine},
year = {2026},
doi = {10.2340/jrm.v58.45826}
}
EUVIMED